temozolomide has been researched along with demethoxycurcumin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fei, X; Shi, L; Wang, Z | 1 |
| Shi, L; Sun, G | 2 |
3 other study(ies) available for temozolomide and demethoxycurcumin
| Article | Year |
|---|---|
Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells.
Topics: Apoptosis; Caspase 3; Cell Proliferation; Curcumin; Dacarbazine; Diarylheptanoids; Glioblastoma; Humans; Neoplastic Stem Cells; Primary Cell Culture; Reactive Oxygen Species; Signal Transduction; Temozolomide | 2015 |
Low-Dose DMC Significantly Enhances the Effect of TMZ on Glioma Cells by Targeting Multiple Signaling Pathways Both In Vivo and In Vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cell Line, Tumor; Curcumin; Dacarbazine; Diarylheptanoids; Drug Synergism; G1 Phase; Glioblastoma; Humans; Janus Kinases; Mice; Mice, Nude; Neoplasm Proteins; Reactive Oxygen Species; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
DMC is not better than TMZ on intracranial anti-glioma effects.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Curcumin; Diarylheptanoids; Glioma; Humans; Male; Mice; Mice, Nude; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |